While individual needs vary, patients often continue treatment to maintain results and manage chronic conditions effectively
Personal-or-family MTC, pancreatitis or pancreatic cancer, gastroparesis, IBD, hypertriglyceridemia, kidney injury, 6-month bariatric recency, a named GLP-1 brand allergy screen, and a named diabetes drug interaction screen covering sulfonylureas and DPP-4 inhibitors
This may make these medications challenging or unappealing to some individuals, as the medications need to be refrigerated and injected subcutaneously (under the skin)
[13] [14] The SUSTAIN-6 trial also demonstrated a reduction in major adverse cardiovascular events in patients with type 2 diabetes at high cardiovascular risk, though this is not a specific licensed indication in the UK
SULT2A (SULT2A1) and SULT2B (SULT2B1a and SULT2B1b) belong to SULT2 family